141286-90-0

Basic information

• Product Name: 2-Propenoic acid, 3-[4-(hydroxymethyl)phenyl]-, methyl ester
• CAS NO: 141286-90-0
• Molecular Formula: C11H12O3
• Molecular Weight: 192.214
• Mol File: 141286-90-0.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: 2-Propenoic acid, 3-[4-(hydroxymethyl)phenyl]-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Propenoic acid, 3-[4-(hydroxymethyl)phenyl]-, methyl ester(141286-90-0)
• EPA Substance Registry System: 2-Propenoic acid, 3-[4-(hydroxymethyl)phenyl]-, methyl ester(141286-90-0)

Safety Data

• Hazardous Substances Data: 141286-90-0(Hazardous Substances Data)

Upstream product

• 58045-41-3 methyl 3‐(4‐formylphenyl)acrylate 
• 619-66-9 4-Carboxybenzaldehyde 
• 292638-85-8 acrylic acid methyl ester 
• 67-56-1 methanol 
• 7560-50-1 methyl (2E)-3-(4-formylphenyl)acrylate 
• 66885-68-5 (E)-p-formylcinnamic acid 
• 115974-97-5 methyl (E)-4-carboxyl cinnamate 

Downstream Products

• 283153-64-0 methyl 3-(4-(hydroxymethyl)phenyl)propanoate 
• 731846-75-6 methyl (E)-3-(4-(chloromethyl)phenyl)acrylate 
• 1353660-67-9 C₃₈H₅₆N₄O₈Si 
• 1353660-71-5 C₃₇H₅₄N₄O₈Si 
• 1353660-77-1 C₅₂H₈₀N₄O₁₀Si 
• 1353660-32-8 (2S,3R)-methyl 3-(4-((tert-butyldimethylsilyloxy)methyl)phenyl)-2,3-dihydroxypropanoate 
• 1353660-40-8 (2S,3S)-methyl 3-azido-3-(4-((tert-butyldimethylsilyloxy)methyl)phenyl)-2-hydroxypropanoate 
• 1353660-49-7 (2S,3S)-methyl 3-azido-3-(4-((tert-butyldimethylsilyloxy)methyl)phenyl)-2-methoxypropanoate 
• 1353660-58-8 (2S,3S)-methyl 3-amino-3-(4-((tert-butyldimethylsilyloxy)methyl)phenyl)-2-methoxypropanoate 
• 1018674-58-2 cyclopentyl 4-(4-{3-[(1-isobutoxyethoxy)amino]-3-oxopropyl}benzyl)piperazine-2-carboxylate 
• 1018674-56-0 3-[4-({4-[(benzyloxy)carbonyl]-3-[(cyclopentyloxy)carbonyl]piperazin-1-yl}methyl)phenyl]propanoic acid 
• 1018674-57-1 1-benzyl 2-cyclopentyl 4-(4-{3-[(1-isobutoxyethoxy)amino]-3-oxopropyl}benzyl)piperazine-1,2-dicarboxylate 
• 34961-64-3 4-formyldihydrocinnamic acid 
• 56703-34-5 3-[4-(hydroxymethyl)phenyl]propanoic acid 

Relevant articles and documents

NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, isomers thereof, or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions comprising the same, a method of treating disease using the composition, and methods for preparing the novel compounds. The novel compounds according to the present invention have histone deacetylase 6 (HDAC6) inhibitory activity, and are effective for the prevention or treatment of HDAC6-associated diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders.

Synthesis of chondramide a analogues with modified β-tyrosine and their biological evaluation

Starting from cinnamates 9, obtained by Wittig reaction or Heck coupling, the diols 17 were prepared by asymmetric dihydroxylation. This was followed by a regioselective substitution of the 3-OH group with hydrazoic acid under Mitsunobu conditions. Methylation of the 2-OH group and reduction of the azide group led to the β-tyrosine derivatives 8. Condensation with the dipeptide acid 6 furnished the tripeptide part of the chondramides. The derived acids 21 were combined with the hydroxy ester 7 to the esters 22. Cleavage of the tert-butyl groups and intramolecular lactam formation gave rise to the chondramide A analogues 2 b-k. Growth inhibition assays showed most of the analogues to be biologically active. Some of them even reach the activity of jasplakinolide. It can be concluded that the 4-position of the aryl ring in the β-tyrosine of chondramide A tolerates structural modifications quite well.

The binding of synthetic retinoids to lipocalin β-lactoglobulins

The binding of therapeutically relevant synthetic retinoid derivatives to bovine and reindeer β-lactoglobulin (βLG) is demonstrated using fluorescence quenching and ultrafiltration/HPLC methods. Furthermore, synthesis of methyl (E)-3-[4-[(E)-2-(2,6,6-trimethylcyclohex-1-enyl)vinyl]phenyl]-acrylate 4 and (E)-3-[4-[(E)-2-(2,6,6-trimethylcyclohex-1-enyl)vinyl]phenyl]acrylic acid 5 is described. All studied compounds bind to both βLG homologues with nanomolar Kd values, and the interaction diminishes the pH-dependent aggregation of retinoids. Thus, βLG may show benefits in improving the bioavailability of retinoid derivatives.